Associated tags: CPR, Asahi Kasei, Data management, EMS, Ventilation, Temperature, Health, Medical Devices, Biotechnology, FDA, Patient, Cardiology, Software, Hamad Medical Corporation, Clinical Trials, Other Technology, Hospital, Medical device
Locations: MASSACHUSETTS, UNITED STATES, NORTH AMERICA
Surgery,
Medical Devices,
Hospitals,
Health,
Cardiology,
Angioplasty,
Asahi Kasei,
Patient,
Cardiac muscle,
Facial muscles,
Mortality,
Splenic infarction,
AUC,
STEMI,
LAD,
Heart,
Safety,
Patient safety,
FDA,
Nursing ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.
Key Points:
- ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.
- Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program.
- Through its Innovative Technology Program , Vizient works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare.
- Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
Retrieved on:
Thursday, February 8, 2024
Cardiology,
Software,
Practice Management,
Health,
Medical Devices,
Hospitals,
Health Technology,
Technology,
Certification,
Asahi Kasei,
European,
MDR,
Resuscitation,
Safety,
Council,
CE,
European Parliament,
Medical device ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the ZOLL AED 3® defibrillator is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR.
Key Points:
- ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the ZOLL AED 3® defibrillator is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR.
- EU MDR is the European Union Medical Device Regulation 2017/745 that was released in 2017 by the European Parliament and the Council of the European Union.
- ZOLL has now obtained CE marking for the ZOLL AED 3 defibrillator under the EU MDR.
- “This is the most stringent level of European medical regulation for a medical device and represents ZOLL’s long-standing commitment to product quality, safety, and efficacy.”
ZOLL continues to work diligently toward achieving EU MDR approval and certification for ZOLL’s full portfolio of products.
Retrieved on:
Monday, December 18, 2023
ZOLL Medical Corporation (“ZOLL”) is notifying individuals who were in contact with ZOLL Respicardia either directly or indirectly through a provider, or whose provider contacted ZOLL Respicardia on their behalf, that their health information may have been accessed by an unauthorized party after a ZOLL employee was the victim of a sophisticated email phishing attack.
Key Points:
- ZOLL Medical Corporation (“ZOLL”) is notifying individuals who were in contact with ZOLL Respicardia either directly or indirectly through a provider, or whose provider contacted ZOLL Respicardia on their behalf, that their health information may have been accessed by an unauthorized party after a ZOLL employee was the victim of a sophisticated email phishing attack.
- This incident was limited to emails and had no impact on ZOLL’s medical devices, software, or services.
- The information affected by the incident may have included some individuals’ names and health information.
- ZOLL is evaluating its cybersecurity education and training measures for employees.
Retrieved on:
Monday, December 18, 2023
ZOLL Medical Corporation (“ZOLL”) is notifying some ZOLL employees, dependents and beneficiaries (current and former) that their protected health information (PHI) may have been accessed by an unauthorized party after a ZOLL employee was the victim of a sophisticated email phishing attack.
Key Points:
- ZOLL Medical Corporation (“ZOLL”) is notifying some ZOLL employees, dependents and beneficiaries (current and former) that their protected health information (PHI) may have been accessed by an unauthorized party after a ZOLL employee was the victim of a sophisticated email phishing attack.
- This incident was limited to emails and had no impact on ZOLL’s medical devices, software, or services.
- ZOLL has no indication that the information has been misused.
- ZOLL is notifying affected individuals by mail and offering free credit monitoring and identity theft protection services.
Technology,
Medical Devices,
FDA,
Other Technology,
Clinical Trials,
Cardiology,
Software,
Biotechnology,
General Health,
Health,
Nursing,
BRAIN,
Asahi Kasei,
Temperature,
Hospital The agreement expands ZOLL’s portfolio of temperature management solutions to include both intravascular technology and surface options — providing clinicians with choices for advanced solutions with precise temperature control and intelligent analytics.
Key Points:
- The agreement expands ZOLL’s portfolio of temperature management solutions to include both intravascular technology and surface options — providing clinicians with choices for advanced solutions with precise temperature control and intelligent analytics.
- The BrainCool™ System (branded the IQool™ System in the United States) is an advanced surface temperature management system with gel-free and adhesive-free pads that maintains fever control and manages patient temperature in critical care settings.
- The IQool System features an intuitive user interface, programmable protocol settings and acute temperature control.
- “Expanding ZOLL’s temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives,” stated Christopher Barnabas, President of ZOLL Circulation.
Other Health,
Radiology,
Hardware,
Medical Devices,
Technology,
Health Technology,
Cardiology,
Biotechnology,
Neurology,
Other Technology,
FDA,
Health,
Life,
Central sleep apnea,
CSA,
Respiration,
Diaphragm,
Spine,
Asahi Kasei,
Brain,
MRI,
Magnetic resonance imaging,
Patient,
Hamad Medical Corporation,
Phrenic nerve,
Longevity,
Medical imaging,
Medical device ZOLL’s remedē System is an implantable transvenous phrenic nerve stimulation therapy for the treatment of adults with moderate to severe Central Sleep Apnea (CSA).
Key Points:
- ZOLL’s remedē System is an implantable transvenous phrenic nerve stimulation therapy for the treatment of adults with moderate to severe Central Sleep Apnea (CSA).
- Full-body MRI approval applies to all models of remedē System, covering new remedē patients as well as those who already have a remedē device.
- Approval of the remedē System for conditional use with MRI will allow those patients to now have access to this important therapy,” said Dr. Asim Roy, medical director of the Ohio Sleep Medicine Institute.
- FDA approval to use full-body MRI on remedē patients is a significant milestone for ZOLL and the remedē therapy.”
The remedē System was approved by the FDA in 2017.
Cardiology,
Software,
Biotechnology,
Health,
FDA,
Medical Devices,
Technology,
Clinical Trials,
Penn State Milton S. Hershey Medical Center,
Penn State Health Children's Hospital,
MD,
Asahi Kasei,
Hospital,
Physician,
Mortality,
BMAD,
Paul Zoll,
Clinical trial,
World Heart Federation,
Patient,
Benefit,
Heart failure,
Hamad Medical Corporation,
American College,
Syndrome,
Pharmaceutical industry,
Medical device Based on BMAD Trial results, ZOLL Heart Failure Management System (ZOLL HFMS) reduced 90-day heart failure hospital readmission by 38% (p=0.03).1 To learn more, view BMAD Trial clinical results .
Key Points:
- Based on BMAD Trial results, ZOLL Heart Failure Management System (ZOLL HFMS) reduced 90-day heart failure hospital readmission by 38% (p=0.03).1 To learn more, view BMAD Trial clinical results .
- ZOLL HFMS is non-invasive and can be worn by patients 24 hours a day.
- Certified technicians from the ZOLL Independent Diagnostic Testing Facility monitor data from ZOLL HFMS and provide physicians with timely notifications based on patient-specific trends according to predefined criteria.
- The system is intended for patients following an acute heart decompensation event that resulted in a hospitalization or clinic visit.
Retrieved on:
Tuesday, January 11, 2022
Data,
Health care,
Government,
Multimedia,
Health,
Patient,
Asahi Kasei,
Policy,
CEO,
Efficiency,
Solution,
Emergency medical services,
Health insurance Together, they deliver best-in-class patient access and workflow efficiency for medical and pharmacy benefits.
Key Points:
- Together, they deliver best-in-class patient access and workflow efficiency for medical and pharmacy benefits.
- Now, real-time medical benefits, patient financial responsibility, insurance discovery, and electronic prior authorization will be available to an expanding network of providers via the ZOLL AR Boost solution and Myndshft.
- Myndshft and ZOLL Data Systems are collaborating to tackle complex workflows like prior authorization challenges for healthcare providers.
- Both the Myndshft and ZOLL Data Systems solutions utilize innovative technology to explore every coverage option and payer source rules for patients.
Retrieved on:
Monday, September 13, 2021
Medical Devices,
Health,
Technology,
Software,
Cardiology,
Hardware,
ZOLL Medical Corporation,
Asahi Kasei,
Itamar Medical Ltd,
ZOLL MEDICAL CORPORATION,
ASAHI KASEI,
ITAMAR MEDICAL LTD ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway, today announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.
Key Points:
- ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway, today announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.
- ZOLL Medicals acquisition of Itamar Medical is subject to approval by the shareholders of Itamar Medical, regulatory approvals and other customary closing conditions.
- Goldman Sachs & Co. LLC is acting as financial advisor to ZOLL Medical, and Cooley LLP and Gornitzky & Co. serve as legal advisors to ZOLL Medical.
- Itamar Medical is a registered trademark of Itamar Medical Ltd. in the United States and/or other countries.
Other Manufacturing,
Technology,
Medical Devices,
Other Technology,
Cardiology,
Software,
Manufacturing,
Other Health,
Hardware,
Health,
EMS,
National Academies Press,
Indian Journal of Critical Care Medicine,
Wallaby,
Stroke,
Ammonia,
Time,
Critical Care Medicine (journal),
GBD,
Survival,
Life,
Intracranial aneurysm,
Esperance,
Dialysis,
Asahi Kasei,
The Lancet,
Data management,
Ventilation,
National Academy of Medicine,
Cardiac arrest,
Health,
National academy,
Hamad Medical Corporation,
Temperature,
Health care,
Patient,
TTM,
Survivor,
Solution,
CEO,
Howard Johnson Co. v. Detroit Local Joint Executive Board,
FDA,
CPR,
Medical device,
Pharmaceutical industry,
ZOLL Medical Corporation,
Asahi Kasei,
Wallaby Medical,
ZOLL MEDICAL CORPORATION,
ASAHI KASEI,
WALLABY MEDICAL ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Wallaby Medical Technologies, a medical device company dedicated to treating stroke and cardiac arrest, today announced they have signed a distribution agreement whereby Wallaby will manage the sales and distribution of ZOLLs temperature management products in China.
Key Points:
- ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Wallaby Medical Technologies, a medical device company dedicated to treating stroke and cardiac arrest, today announced they have signed a distribution agreement whereby Wallaby will manage the sales and distribution of ZOLLs temperature management products in China.
- ZOLL is excited to work with Wallaby to further expand the use of the Thermogard XP in China, allowing more patients to benefit from high-quality targeted temperature management (TTM), said Neil Johnston, President, ZOLL Circulation.
- The Thermogard XP Intravascular Temperature Management System is an important part of our comprehensive product portfolio to achieve that aim, said Michael Alper, CEO, Wallaby Medical.
- IVTM, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.
